Kinfo
Opus Genetics Inc. logo

Opus Genetics Inc.

OCUPNASDAQHealthcare·US · USD
$4.41
+0.03 (+0.68%)
Prices as of October 7, 2026 · live

Price

Key statistics

Valuation
Market cap105.74M USD
Enterprise value0.00 USD
Trailing P/E1.38
Forward P/E-1.30
PEG ratio0.00
Price / sales5.55
Price / book3.36
Profitability
Gross margin0.00%
Operating margin-52.36%
Profit margin0.00%
Return on assets-18.51%
Return on equity-20.01%
Income (TTM)
Revenue19.05M USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-9.99M USD
Diluted EPS-$0.46
Rev. growth (YoY)247.75%
Balance sheet
Total cash0.00 USD
Total debt0.00 USD
Debt / equity0.00
Current ratio6.63
Book value / share$1.31
Cash flow (TTM)
Operating cash flow-1.54M USD
Levered free cash flow-9.99M USD
Shares & price
Shares outstanding25.98M
Float0.00
Held by institutions0.00%
Beta0.00
50-day MA$0.00
200-day MA$0.00
52-week high$7.07
52-week low$1.70
Earnings (EPS)
DateEst.ActualSurprise2025-12-05-0.02-0.10−400.00%2025-11-043.163.01−4.75%2024-08-13-0.28-0.30−7.14%2024-05-10-0.14-0.29−107.14%2024-03-08-0.05-0.21−320.00%
About Opus Genetics Inc.

Opus Genetics Inc. is a biotechnology company focusing on developing innovative gene therapies for inherited retinal diseases. Their primary mission is to address unmet medical needs for patients suffering from these rare genetic conditions that often lead to severe visual impairment or blindness. Opus Genetics leverages advanced gene therapy techniques to design and deliver solutions that target the root causes of such vision disorders. By concentrating on the sensory system, particularly the eyes, they aim to restore vision or significantly stall disease progression. The company operates at the intersections of genetic research, clinical development, and ophthalmology, influencing the broader healthcare and medical research sectors. As part of a niche but crucial industry within biotechnology, Opus Genetics plays a significant role in pioneering treatments that could potentially transform the lives of those affected by genetic ocular diseases. Their work underscores the vital importance of breakthrough biomedical research and innovation in improving quality of life for patients with chronic and debilitating conditions.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. George Magrath M.B.A., M.D., M.S.
Employees
18
Headquarters
Durham, NC, United States

Frequently asked questions about Opus Genetics Inc.